INVO Fertility Inc. (NASDAQ:IVF) shares are trending on Wednesday.
Shares of the Florida-based healthcare company fell 14.78% to $2.02 in after-hours trading on Tuesday.
According to Benzinga Pro data, IVF closed the regular session at $2.37, up 191.73%.
No immediate reason has been identified for the stock movements.
On Jan. 15, INVO Fertility, formerly known as NAYA Biosciences, participated in the Lytham Partners 2026 Investor Healthcare Summit, a virtual event featuring fireside chats with public company executives discussing company performance and sector outlook.
Family Beginnings Acquisition Agreement Signed
The company signed a definitive purchase agreement in December 2025 to acquire Family Beginnings, P.C., an Indiana-based fertility clinic.
According to an INVO Fertility press release, the $750,000 purchase price includes $350,000 in cash payable at closing, less a $150,000 holdback, and $400,000 in Series D nonvoting convertible preferred stock. Family Beginnings generated approximately $1.2 million in revenue and $200,000 in net income for the 12 months ended Sept. 30, 2025.
The transaction is expected to close by Feb. 27.
Third Quarter Shows Revenue Growth
In November 2025, INVO reported third-quarter 2025 revenue of $1,757,094, up 23% from $1,433,151 in the same period of 2024. Consolidated clinic revenue from the company’s INVO Center in Atlanta and its fertility clinic in Madison, Wisconsin, rose 21% to $1,722,223.
The company posted a net loss of $2.6 million, compared with a $1.6 million loss a year earlier.
CEO Steve Shum cited “higher patient volume and increased awareness” as drivers.
Trading Metrics, Technical Analysis
INVO Fertility has a market capitalization of $5.67 million, with its stock trading in a 52-week range of $0.71 to $148.20.
The Relative Strength Index (RSI) of the stock stands at 72.66.
INVO Fertility, Inc. stock has declined 98.25% over the past 12 months, reflecting significant challenges over the year. This long-term trend highlights the volatility and risk associated with the stock, even as it shows some signs of short-term recovery.
The stock is near the low end of its 52-week range, trading just 1.13 percent above the bottom. This highlights uncertainty about its future price movements. Traders should be cautious, as the stock could be vulnerable to further declines if recent bullish momentum fades.
Benzinga’s Edge Stock Rankings indicate that IVF is showing short-term upward momentum while experiencing medium- and long-term consolidation.
Photo Courtesy: Zakharchuk on Shutterstock.com
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Recent Comments